Multicomponent meningococcal B vaccine (recombinant, adsorbed)


Multicomponent meningococcal B vaccine (recombinant, adsorbed)

Drug updated on 4/24/2024

Dosage FormInjection (intramuscular; 0.5 mL [50 mcg])
Drug ClassVaccines
Ongoing and
Completed Studies


  • Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Bexsero is approved for use in individuals aged 10 through 25 years.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Multicomponent meningococcal B vaccine (recombinant, adsorbed) (Bexsero) is indicated for active immunization of individuals from 2 months through 25 years old against invasive disease caused by Neisseria meningitidis serogroup B strains.
  • The analysis is based on a systematic review/meta-analysis regarding the safety and effectiveness of Bexsero.
  • Bexsero has an acceptable short-term safety profile with an incidence rate of potentially vaccine-related acute serious adverse events recorded at 5.74 per 1000 individuals. Although this rate is higher compared to routine vaccines, it indicates that Bexsero is relatively safe, albeit with slightly more risk.
  • High rates of seroconversion were observed after the primary vaccination course, indicating a strong initial immune response; however, long-term immunogenicity showed some decline, especially against certain strains, without booster dose administration.
  • Efficacy in inducing seroconversion varies between children and adolescents; adequate long-term immunogenicity was observed in adolescents for three strains, while only two strains showed adequacy before introducing a booster in children.
  • A booster dose significantly increased the proportion achieving seroconversion across all strains, reaching above 93%, underlining its importance for maintaining prolonged protection, particularly among younger children.

Product Monograph / Prescribing Information

Document TitleYearSource
Bexsero (multicomponent meningococcal B vaccine [recombinant, adsorbed]) Prescribing Information.2023GlaxoSmithKline Inc., Mississauga, Ontario

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines